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Abstract
The use of a single swab for both MRSA culture and for rapid testing by PCR was evaluated, using the Hain GenoQuick (GQM)
methicillin resistant Staphylococcus aureus (MRSA) assay for the rapid detection of MRSA, as a single swab would be the preferred
option for routine diagnostic testing. GQM detected current prevalent Irish MRSA strains incorporating all known SSCmec types,
including Panton–Valentine leukocidin-positive strains. Using the GQM method, all methicillin-resistant coagulase-negative staphylo-
cocci tested were conﬁrmed to be negative, although three of seven gentamicin-resistant methicillin-sensitive Staphylococcus aureus
strains tested were identiﬁed as MRSA. The theoretical ex-vivo limit of detection of the assay was 704 CFU per GQM assay reac-
tion (1.7 · 104 CFU/mL) when MRSA suspensions were used for DNA extraction, or 1.4 · 103 CFU/swab (1.4 · 104 CFU/mL)
using MRSA absorbed onto Copan screening swabs. Swab processing on chromogenic agar prior to PCR resulted in some inhibi-
tion of the PCR reaction, increasing the limit of detection of the assay by a factor of four. Based on 540 single swab screening
specimens (nasal and groin) processed ﬁrst for culture assay, then by GQM, the speciﬁcity and positive predictive value were both
100%, the negative predictive value was 92%, and the sensitivity was 57%. Culture followed by PCR from a single specimen is not
optimal for the rapid detection of MRSA. Further laboratory validation of the GQM assay is required to determine the true diag-
nostic sensitivity and value of this kit in routine microbiology laboratories, modifying the protocol for single specimens, or using
two specimens.
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Introduction
A major component in the control of methicillin-resistant
Staphylococcus aureus (MRSA) transmission is the early detec-
tion of patients either colonized or infected with MRSA, fol-
lowed by isolation to prevent cross-infection [1]. Several
studies evaluating the accuracy of various MRSA detection
kits (IDI MRSA: Cephid, Maurens-Scopont, France; GeneX-
pert MRSA: Cephid, Sunnyvale, CA, USA; GenoType MRSA:
Main Life Science, Nehren, Germany; and the MRSA EVIGE-
NETM: Statens Serum Institut, Copenhagen, Denmark) and
PCR in-house assays [2–8] have been published. The Hain
GenoQuick (GQM) MRSA assay (Hain Lifescience, Nehren,
Germany) is a new molecular assay. Its predecessor, Geno-
Type MRSA, is a PCR assay using DNA Strip technology for
amplicon detection, and permits the identiﬁcation of
S. aureus, S. epidermidis, and the mecA gene, with a specimen
turn-around time of c. 7 h [7,9]. GQM is based on the same
immuno-chromatographic detection technology, but detects
MRSA with a reported turn-around time of only c. 2.5 h.
MRSA-speciﬁc chromosomal sequences are targeted. The
assay consists of three steps: direct DNA extraction from
a patient swab using a lysis buffer provided, followed by
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multiplex PCR (primer/probe/nucleotide mix provided) with
single-stranded amplicon hybridization using a speciﬁc probe,
and ﬁnally, the detection of amplicon/probe complex—the
complex selectively binds to the test band on the dipstick
and is visualized by gold labelling. Each dipstick includes two
control zones: a conjugate control zone to check the binding
of the conjugate on the dipstick and an ampliﬁcation control
zone to check for a successful ampliﬁcation reaction.
Here we determined the accuracy and the limit of detec-
tion (LoD) of the GQM assay and established the potential
to use one MRSA screening swab for two methods of MRSA
detection. This specimen process ﬂow is preferred where
diagnostic laboratories choose to continue culture with PCR
for conﬁrmation, and to use the isolate for epidemiological
purposes. Additionally, this ﬂow enables adherence to
accredited laboratory standard operating procedures, mini-
mizing the additional nursing, laboratory and administrative
workloads, and the ﬁnancial burden associated with taking
and processing two specimens.
Methods
Bacterial isolates
The capacity of the GQM assay to detect Irish MRSA strains
(n = 32) was assessed using a collection provided by the
National MRSA Reference Laboratory, Dublin and Dublin
Dental School and Hospital, Trinity College Dublin [10,11].
All isolates were tested, according to manufacturer’s instruc-
tions, for pure culture analysis. This isolate group comprised
28 isolates representative of common epidemiological types
recovered in Ireland and four control strains, including
the following SCCmec types (I, IA, II, IIA–IIE, III, IIIv, IV and
IVa–IVh, V, VI).
Two reference strains, MRSA-ATCC 43300 and methicil-
lin-sensitive Staphylococcus aureus (MSSA)-ATCC 29213, were
included. A further seven gentamicin-resistant methicillin-
susceptible Staphylococcus aureus (GrMSSA) strains [12] and
eight various methicillin-resistant coagulase-negative staphylo-
cocci (MRCNS) were also tested.
Conventional culture and MRSA identiﬁcation
MRSA screening specimens were collected using single
Copan 151C cotton albumin coated swabs (Medical Supply
Company, Dublin, Ireland) as per laboratory standard oper-
ating procedures. The GQM assay does not specify what
type of swab is optimal for use. Swabs were assessed for the
presence of MRSA by plating on MRSA Select chromogenic
media (CA) for the isolation and identiﬁcation of MRSA
(Bio-Rad Life Science Group, Marnes-la-Coquette, France).
Colonies deemed positive on this media were subcultured
on Columbia Blood Agar (CBA) (Cruinn, Ireland) and con-
ﬁrmed by slide coagulase (Staphaurex Plus, Remel; Oxoid
Ltd., Basingstoke, UK) and by automated antibiotic suscepti-
bility testing (Phoenix, BD Biosciences, Pharmingen, CA,
USA).
Limit of detection assays
LoD assays (n = 3) of the GQM assay were performed as
follows: A 0.5 McFarland of strain MRSA ATCC 43300 was
prepared in saline and a ten-fold dilution series was made.
CFU per millilitres was determined by spread plating each
dilution on CBA and incubating at 37C for 24 h.
To calculate the LoD of the assay when MRSA suspen-
sions were used directly for DNA extraction protocols,
40 lL of each dilution above was added to 260 lL of buffer
Q-LYS supplied in the GQM kit. Subsequent extraction of
these 300-lL preparations, PCR and ELISA-based detection
were performed as per the manufacturers’ instructions.
To calculate the LoD when MRSA suspensions were
absorbed onto Copan screening swabs prior to DNA extrac-
tion, 100 lL of each dilution above was adsorbed onto indi-
vidual swabs. The swabs were allowed to dry for 30 min
before vigorous vortexing in 300 lL of buffer Q-LYS and
GQM processing.
Using the CFU/mL count determined above, the LoD of
each reaction was determined, and the equivalent CFU/mL
was calculated. LoD were recorded as the lowest concentra-
tion that produced a GQM assay positive reaction.
GQM assay inhibition by CA agar
To establish if culturing screening specimens on CA prior to
GQM processing resulted in any PCR reaction inhibition, the
following experiment was carried out (n = 3). A ten-fold dilu-
tion series of a 0.5 McFarland S. aureus ATCC 43 300 was
made in 1-mL volumes of sterile saline. Forty microlitres of
each dilution was added to 260 lL of GQM buffer Q-LYS. A
duplicate set of dilutions was prepared. In the ﬁrst set, sterile
Copan swabs were rubbed on CA plates immediately before
washing in each 300 lL dilution sample and processing by
GQM. In the second set, sterile Copan swabs that had not
been exposed to CA agar were washed in each 300-lL dilution
and processed by GQM. The number of CFU per dilution was
determined by spread plating (as for LoD above). LoD results
from the two sets were compared, to determine if rubbing the
swab on CA prior to PCR had an inhibitory affect.
GQM version 2.0
All tests were performed according to the manufacturer’s
instructions except that specimens were cultured on CA
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prior to washing the swab in lysis buffer. The PCR ampliﬁ-
cation mix consisted of 35 lL primer nucleotide mix, 5 lL
10· polymerase buffer, 0.5 lL of 25 mM MgCl2 0.3 lL
Fast start Taq (5 U per lL) (Roche, Basel, Switzerland),
5 lL DNA template and 4.2 lL water. The ampliﬁca-
tion protocol was according to the manufacturer’s instruc-
tions.
Patient specimen collection and processing
Nasal and groin swabs were collected from patients on var-
ious hospital wards in a 700-bed tertiary referral hospital
with endemic MRSA, over an 8-week period, as part of
routine MRSA screening measures. Five hundred and forty
specimens from 250 patients were collected and processed
(270 groin and 270 nasal). Swabs were cultured on CA
plates before processing by GQM. Discrepant results were
further examined as follows. Swabs that were PCR positive
but culture negative were cultured a second time, but were
enriched overnight in 5 mL of tryptone salt broth 6% NaCl
(37C at 150 rpm in a shaking incubator) and subsequently
plated on CA. Specimens that were PCR negative but cul-
ture positive were tested a second time by GQM PCR,
using 5 lL of the 300 lL extracted specimens. Additionally,
MRSA isolates recovered from discrepant specimens were
tested by PCR in pure culture as per manufacturer’s
instructions.
Results
Analytical sensitivity and speciﬁcity
The GQM assay detected all MRSA strains in a collection
representative of MRSA in Ireland since 1974 (n = 32). All
eight MRCNS tested negative. Of seven GrMSSA strains
tested, three tested positive by PCR and are considered false
positives.
LoD assays
Using a saline dilution series and colony formation for cali-
bration, when MRSA suspensions were used directly for
DNA extraction and subsequent GQM ampliﬁcation, the
LoD was determined to be 704 CFU/GQM reaction (equiva-
lent to a calculated 1.7 · 104 CFU/mL). As only 5 lL of the
extracted 300 lL DNA preparations can be used as template
in the GQM PCR reaction, this translates to an LoD per
PCR of 11.8 CFU.
The LoD when MRSA suspensions were adsorbed onto
Copan screening swabs prior to DNA extraction and subse-
quent GQM ampliﬁcation was determined to be 1.4 · 103
CFU/swab, equivalent to a calculated 1.4 · 104 CFU/mL.
Chromogenic agar inhibits the Hain GQM assay
In a GQM reaction where a swab was washed in GQM buffer
Q-LYS containing a known number of MRSA cells, the lowest
number of MRSA detected was 1.4 · 103 CFU/reaction. By
contrast, where the swab was ﬁrst rubbed on a CA plate and
then washed in GQM buffer Q-LYS containing the same
number of MRSA cells as above, the lowest number of MRSA
detected was 5.6 · 103 CFU/reaction, suggesting that
processing of swabs on CA prior to GQM PCR does have an
inhibitory effect and increases LoD per reaction or CFU/mL
by a factor of four.
Clinical specimens
Of 540 specimens processed 47/540 (8.7%) were both PCR
and culture positive and 451/540 (83.5%) were negative by
both methods. Discrepant results occurred with 42/540
(7.7%) specimens; four were PCR positive but culture nega-
tive and 38 were PCR negative but culture positive. All four
patients with a positive PCR and culture-negative result had
been decolonized and thus were considered true MRSA pos-
itives. The amended MRSA positive rate was therefore calcu-
lated as 51/540 (9.4%), with a discrepant rate of 38/540
(7.0%). For these remaining 38 discrepant results (PCR-nega-
tive/culture-positive specimens), PCR analysis of the pre-
pared DNA extracted/lysis reactions was repeated and all
were conﬁrmed negative.
All 38 swabs were plated a second time on CA and subse-
quently enriched in Tryptic Soy Broth (TSB), for 24 h
followed by plating on CA. Twelve grew after direct plating
and enrichment, suggesting that the microorganisms were
present on the swabs but were not detected by PCR. PCR
on all 12 of these isolates (colony tested) were PCR positive,
therefore these were considered true PCR false negatives in
terms of the predictive value of the PCR assay.
Staphylococcus aureus was not isolated again after repeat
culture with enrichment in TSB for the remaining 26/38
discrepant specimens. These were considered false negatives.
The sensitivity, speciﬁcity, positive predicative value (PPV)
TABLE 1. Sensitivity, speciﬁcity, PPV and NPV of the Hain
GQM assay
PCR
positive
PCR
negative
Sensitivity
(%)
Speciﬁcity
(%)
PPV
(%)
NPV
(%)
Culture
positive
51 38 57 100 100 92
Culture
negativea
0 451 – – – –
PPV, positive predictive value; NPV, negative predictive value.
Note: aFour samples found to be culture negative, PCR positive were deemed
to be false negatives, derived from decolonized patients, and are included as cul-
ture positives.
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and negative predictive value (NPV) were calculated (Table 1).
Discussion
Conference proceedings by Eigner et al. [13] report on an
evaluation of the GQM assay, reporting it as 100% sensitive,
with a speciﬁcity of 99.4%, PPV 96% and NPV 100%, whereas
Boegli-Stuber [14] report a GQM sensitivity of 91.3%. These
results were promising, as GQM was 50% cheaper than
other molecular methods and could provide a cost-effective
alternative for rapid MRSA diagnostics. Additionally, this
study showed that GQM detects SCCmec types I–V,
whereas MSSA or coagulase-negative Staphylococci test nega-
tive. Our data support this, with SCCmec VI also being
detected. However, three of seven GrMSSA strains tested
here produced a GQM-positive, culture-negative result.
These strains [12] harbour remnants of SCCmec DNA. As
the majority of commercially available assays use PCR to
detect SCC-associated sequences directly from clinical speci-
mens, a PCR-positive/culture-negative result warrants cau-
tion and further investigation, e.g. culture on non-selective
media for isolate characterization.
The LoD of GQM can be reported in a number of ways.
Here we established the LoD of the complete GQM assay
to be 704 CFU. This is the minimum number of MRSA cells
required to give a positive hybridization signal when added
to the GQM extraction mix. LoD can also be expressed as
LoD per PCR and this has been calculated as 11.8 CFU per
PCR. Many studies report LoD of rapid assays in CFU per
mL or CFU per swab, thus our GQM LoD results can also
be reported as 1.4 · 104 CFU/mL or 1.7 · 103 CFU/swab.
By contrast, the LoD of other rapid methods has been
reported as 6.1 · 102 CFU/mL or 5.8 · 101 CFU/swab for
GeneXpert and 1.7 · 102 CFU/swab for routine MRSA chro-
mogenic culture [4].
Processing clinical specimens on CA with subsequent
GQM ampliﬁcation, as described here, results in a discrepant
rate of 7% (38 specimens were PCR negative, culture posi-
tive). Twelve of the 38 discrepant specimens reported as
PCR negative/culture positive were culture positive both
prior to GQM processing and when cultured a second time
after discharge in the Q-LYS lysis buffer, suggesting that
these were false negatives by GQM.
However, 26/38 specimens that were culture positive/PCR
negative were not culture positive after a second culture
attempt following discharge in the GQM buffer Q-LYS solu-
tion. Some possible explanations for these discrepancies
include: (i) discrepancy due to this workﬂow, i.e. processing
by culture before GQM removed all organisms from the
swab, hence a GQM negative result; (ii) PCR inhibition
resulted from rubbing the swab on a CA plate prior to
GQM processing; (iii) the lysis reaction may have failed or
may not have been optimal; and (iv) these 26 specimens
were not detected as GQM positive because inoculum levels
were below the LoD of the GQM assay. Calculations of the
assay sensitivity depend on the interpretation of these
ﬁndings. If we excluded the 26 GQM-negative, culture-posi-
tive specimens from sensitivity calculations, assuming that
because of the work ﬂow used all organisms had been
removed by culture prior to PCR or that CA inoculation
resulted in inhibition, a GQM sensitivity of 81% would have
been achieved. Including the 26 specimens in the sensitivity
calculation but assuming that all 26 specimens would have
been PCR positive/culture positive if specimens had been
processed by PCR ﬁrst followed by culture would result in
an improved sensitivity of 87%. However, the actual sensitiv-
ity determined here was 57%. The true value for the sensi-
tivity value is at best between 81% and 87% but at worst
between 57% and 81%, depending on the interpretation of
the PCR-negative, culture-positive discrepant results. A full
study to establish the diagnostic sensitivity of Hain GQM
would be valuable.
We acknowledge the limitations in our evaluation, which
include the number of specimens tested, conﬁning the testing
to nasal and groin specimens only (other licensed specimens
include throat and wounds), and the taking of only one
specimen per site for both PCR and culture.
Although an evaluation of two swabs per site, i.e. one for
PCR and one for culture, might have led to fewer discrepant
results, this represents considerable additional processing
time and expense for routine diagnostic laboratories. Addi-
tionally, we did not want to alter the accredited method of
culture as this was an evaluation in a routine diagnostic set-
ting, thus minimizing any deviations from normal practice
was important. Furthermore, discrepancies may still have
occurred if two specimens had been taken, e.g. due to a
greater load of MRSA being swabbed with the ﬁrst specimen
compared with the second. However, the additional expense
and time incurred should be considered when evaluating
new diagnostic methods.
In summary, whereas agreement of results occurred for
92.3% of specimens processed with culture ﬁrst followed
by PCR, the number of discrepant results and questions
posed by these results suggest that culture followed by
PCR using the one swab is not suitable for routine use. It
is unclear if an alternative swab processing regime would
overcome these shortcomings, but this may result in a
reduced yield from culture. Consequently it is likely that
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where both culture and PCR are being used, two swabs
need to be taken with the resulting time and expense
incurred.
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